The effects of dietary tryptophan manipulation on serotonin and parameters of motor control on healthy adults

Not Applicable

Completed

• Conditions: eurotransmitter level imbalance; Protein supplementation; Neurotransmitter level imbalance; Neurological - Studies of the normal brain and nervous system; Musculoskeletal - Normal musculoskeletal and cartilage development and function; Mental Health - Studies of normal psychology, cognitive function and behaviour

• Registration Number: ACTRN12621001664831
• Lead Sponsor: Karen Mackay

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2020-12-22
• Study Start: 2021-12-03
• Last Update Posted: 13 December 2021

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 16

Inclusion Criteria

non-smokers, BMI <30 kg/m2.

Exclusion Criteria

Musculoskeletal disorders that limit performance in the assessed limb; diagnosed neurological disorders (e.g. amyotrophic lateral sclerosis or ALS); diagnosed serotonergic disorders (e.g. depression); consumption of drugs that affect serotonin and noradrenaline release (e.g. recreational drugs, SRRIs or antidepressants); diagnosed Vitamin D or B6 deficiency; diagnosed with high cholesterol; diagnosed with iron anaemia deficiency. Women must not be pregnant, breast feeding or menopausal.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Changes in maximal voluntary isometric contraction (MVC): Assessed using a leg dynamometer and handgrip transducer.<br><br><br>[Baseline and 90 min after consuming the supplement (on each visit)];Time to fatigue (TTF): Assessed using a leg dynamometer.[Baseline and 2 h after supplement consumption (on each visit)];Changes in estimates of persistent inward currents (PICs): Assessed using high density electromyography (EMG) placed on their triceps surae (gastrocnemius and soleus muscle), while sitting on the leg dynanometer.[Baseline and 90 min after consumption of the supplement (on each visit).]

Secondary Outcome Measures

Name	Time	Method
Primary outcome: Rate of force development (RFD). Assessed using a leg dynamometer.[Baseline and 90 min after consuming the supplement (on each visit)];Primary outcome: - Changes in the brief assessment of mood (BAM), [Baseline, 90 min and 120 min after consuming the supplement (on each visit).];Primary outcome: Cognition: The Trail Maker Test (TMT), [Baseline, 90 min and 120 min after consuming the supplement (on each visit).];Primary outcome: Perception of fatigue (BORG scale),[Baseline and 2 h after consuming the supplement (on each visit)];Primary outcome: Sleepiness (Stanford sleepiness scale).[Baseline, 90 min and 120 min after consuming the supplement (on each visit).]